VelociMab® accelerates antibody development timelines

We developed our VelociMab technology to synergize with the capabilities of the VelocImmune® mouse to accelerate the Regeneron antibody development timelines.

VelociMab enables high-throughput screening of potential therapeutic antibodies and the rapid generation of high-producing Chinese hamster ovary (CHO) cell lines for recombinant human antibodies. VelociMab allows researchers to go from mouse immunization to production cell line bioreactor harvest within eight months, with protein production yields exceeding 1 gram per liter.